Research compounds
Kisspeptin-10
KP-10, metastin fragment
Kisspeptin-10 is the shortest active fragment of kisspeptin, the peptide that sits at the top of the reproductive hormone axis. It has been studied as a fertility diagnostic and as an ovulation trigger, and is not approved.
Also known as: KP-10, kisspeptin 10, metastin, KISS1
- Status
- Kisspeptin-10 is a research compound and not approved by the FDA for human use.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- Approximately 4 minutes for kisspeptin-10.
- How it's taken
- Subcutaneous or intravenous administration in the trial setting
- Mechanism
- Reproductive axis (GnRH / kisspeptin / oxytocin)
- Pathways
- GnRH
How Kisspeptin-10 works
Kisspeptin neurons in the hypothalamus are the master regulators of GnRH release — kisspeptin signalling through the KISS1R receptor is what permits pulsatile GnRH secretion, and loss-of-function mutations cause hypogonadotropic hypogonadism. Because it acts upstream of GnRH, kisspeptin produces a more physiological gonadotropin response than a GnRH agonist.
What research has looked at
- Trials in IVF have used kisspeptin as an ovulation trigger, with a substantially lower rate of ovarian hyperstimulation syndrome than hCG — a genuinely important clinical advantage.
- It has been investigated as a diagnostic probe of hypothalamic function, distinguishing hypothalamic from pituitary causes of hypogonadism.
- Its position upstream of GnRH means it produces an endogenous, physiologically shaped LH surge rather than a supraphysiological one.
- Studies have also examined effects on sexual and emotional brain processing.
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- No kisspeptin product is approved by any regulator despite promising trial results. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- Kisspeptin-10 has a very short half-life, requiring infusion or repeated dosing.
- Manipulating the reproductive axis without monitoring risks disrupting the menstrual cycle or gonadal function.
- Effects are dose- and context-dependent: continuous exposure can desensitise the receptor and suppress the axis, the opposite of the intended effect.
Sources
- PubMed research on kisspeptin-10 IVF trigger ovarian hyperstimulation · NIH · National Library of Medicine
- DrugBank record for kisspeptin · DrugBank
- Active clinical trials for kisspeptin · U.S. National Library of Medicine
Track Kisspeptin-10 in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Kisspeptin-10 FAQ
What is Kisspeptin-10?
Kisspeptin-10 is the shortest active fragment of kisspeptin, the peptide that sits at the top of the reproductive hormone axis. It has been studied as a fertility diagnostic and as an ovulation trigger, and is not approved.
How does Kisspeptin-10 work?
Kisspeptin neurons in the hypothalamus are the master regulators of GnRH release — kisspeptin signalling through the KISS1R receptor is what permits pulsatile GnRH secretion, and loss-of-function mutations cause hypogonadotropic hypogonadism. Because it acts upstream of GnRH, kisspeptin produces a more physiological gonadotropin response than a GnRH agonist.
Is Kisspeptin-10 FDA approved?
No. Kisspeptin-10 is a research compound and not approved by the FDA for human use. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of Kisspeptin-10?
Reported half-life: Approximately 4 minutes for kisspeptin-10.
How is Kisspeptin-10 taken?
Subcutaneous or intravenous administration in the trial setting.
What side effects have been reported with Kisspeptin-10?
Reported in the sources: No kisspeptin product is approved by any regulator despite promising trial results. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; Kisspeptin-10 has a very short half-life, requiring infusion or repeated dosing; Manipulating the reproductive axis without monitoring risks disrupting the menstrual cycle or gonadal function; Effects are dose- and context-dependent: continuous exposure can desensitise the receptor and suppress the axis, the opposite of the intended effect.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.